A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Multiple Myeloma · Relapsed/Refractory Multiple Myeloma

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • HonorHealth, Scottsdale, Arizona, United States

    Contact: Study coordinator (Rizwan Khawaja, MD)
  • Berenson Cancer Center, West Hollywood, California, United States

    Contact: Study coordinator (James Berenson, MD)
  • Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

    Contact: Study coordinator (Nisha Joseph, MD)
  • Indiana University Health, Indianapolis, Indiana, United States

    Contact: Study coordinator (Attaya Suvannasankha, MD)
  • START Midwest, Grand Rapids, Michigan, United States

    Contact: Study coordinator (Andrew Sochacki, MD)
  • Washington University/Siteman Cancer Center, St Louis, Missouri, United States

    Contact: Study coordinator (Mark Schroeder, MD)
  • University of Nebraska Medical Center, Omaha, Nebraska, United States

    Contact: Study coordinator (Sarah Holstein, MD)
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Hamza Hashmi, MD)
  • START San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Kyriakos Papadopoulos, MD)
  • University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin, United States

    Contact: Study coordinator (Natalie Callander, MD)
מובילי המחקר
  • Binod Dhakal, M.D.

    Principal Investigator

    Medical College of Wisconsin

  • Martin Kaiser, M.D.

    Principal Investigator

    The Royal Marsden

  • Aurore Perrot, M.D.

    Principal Investigator

    Universite de Toulouse